Viveve Medical (VIVE) Shares Gap Down to $3.83
Shares of Viveve Medical Inc (NASDAQ:VIVE) gapped down prior to trading on Thursday . The stock had previously closed at $3.94, but opened at $3.83. Viveve Medical shares last traded at $3.75, with a volume of 2835904 shares changing hands.
VIVE has been the topic of a number of research analyst reports. Mizuho initiated coverage on Viveve Medical in a research report on Thursday, November 16th. They issued a “buy” rating and a $10.00 target price on the stock. Cowen set a $11.00 target price on Viveve Medical and gave the company a “buy” rating in a research report on Monday, October 23rd. Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a research report on Thursday, January 4th. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Northland Securities initiated coverage on Viveve Medical in a research report on Friday, January 5th. They issued an “outperform” rating and a $8.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Viveve Medical has a consensus rating of “Buy” and a consensus price target of $10.00.
The stock has a market cap of $101.66, a P/E ratio of -2.06 and a beta of -0.79. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72.
Several large investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its stake in shares of Viveve Medical by 135.1% in the fourth quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock worth $188,000 after acquiring an additional 21,683 shares in the last quarter. ING Groep NV grew its stake in shares of Viveve Medical by 7.7% in the fourth quarter. ING Groep NV now owns 350,000 shares of the company’s stock worth $1,740,000 after acquiring an additional 25,000 shares in the last quarter. Neuberger Berman Group LLC acquired a new position in shares of Viveve Medical in the third quarter worth $419,000. Granahan Investment Management Inc. MA grew its stake in shares of Viveve Medical by 32.6% in the third quarter. Granahan Investment Management Inc. MA now owns 102,147 shares of the company’s stock worth $535,000 after acquiring an additional 25,097 shares in the last quarter. Finally, RTW Investments LP grew its stake in shares of Viveve Medical by 18.8% in the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after acquiring an additional 233,585 shares in the last quarter. Institutional investors and hedge funds own 66.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/10/viveve-medical-vive-shares-gap-down-to-3-83.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.